Press ReleasesFollow CatalYm’s journey and learn more about our most recent milestones April 7, 2026 CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma - Read More December 2, 2025 CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Metastatic Non-squamous NSCLC - Read More October 20, 2025 CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025 - Read More Load MoreLoadingMeet us at the following conferences & events AACR Annual Meeting 2026 Apr 17 - Apr 22, 2026 San Diego Read More EASL Congress 2026 May 27 - May 30, 2026 Barcelona Read More ASCO Annual Meeting 2026 May 29 - June 2, 2026 Chicago Read More BIO International Convention 2026 June 22 - June 25, 2026 San Diego Read More
